STOAF III SciTech och Almi Invest each invests 1.9 MSEK in Developeration AB, who has developed an innovative surgical instrument for treatment of hemmorhoids. The emission of 4.4 MSEK will be used for further product development and clinical trials.
Hemorrhoids affect about 25 percent of the population over the age of 50 in the Western world. There are currently several different ways to treat hemorrhoids, but they carry a high risk of recurrence or complications, are expensive, take a long time, require access to the operating theater, are painful, or a combination of these.
Stockholm-based Developeration has now developed PexyEazy®, an innovative single-use surgical instrument that aims to use the surgical treatment of hemorrhoids. With PexyEazy, the patient does not need to be anesthetized and the operation only takes 10 minutes, which results in significantly less pain and discomfort for the patient. In addition, it provides a cost saving per operation of up to 70 percent for the clinic and the opportunity to perform up to three times more operations per day.
– Developeration has developed an exciting product, based on Johan Ungerstedt’s many years of clinical experience in surgery. We are confident that the company will succeed well and be a good investment for us, says Claes Post, General Partner at STOAF III Scitech.